314 Phase 1 study of abemaciclib, a CDK 4 and 6 inhibitor, as a single agent for Japanese patients with advanced cancer
- DOI
- 10.1016/s0959-8049(16)30179-4
- Published
- 2015-09
- Container
- European Journal of Cancer
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/s0959-8049-16-30179-4,
title = {314 Phase 1 study of abemaciclib, a CDK 4 and 6 inhibitor, as a single agent for Japanese patients with advanced cancer},
author = {S. Kondo and N. Yamamoto and K. Tamura and Y. Tanabe and S. Iwasa and A. Shimomura and Y. Shibasaki and K. Ogasawara and K. Turner-Jones and J. Mori and H. Asou and E. Michael Chan and Y. Fujiwara},
year = {2015},
journal = {European Journal of Cancer},
doi = {10.1016/s0959-8049(16)30179-4},
url = {https://doi.org/10.1016/s0959-8049(16)30179-4}
}RIS
TY - JOUR TI - 314 Phase 1 study of abemaciclib, a CDK 4 and 6 inhibitor, as a single agent for Japanese patients with advanced cancer AU - S. Kondo AU - N. Yamamoto AU - K. Tamura AU - Y. Tanabe AU - S. Iwasa AU - A. Shimomura AU - Y. Shibasaki AU - K. Ogasawara AU - K. Turner-Jones AU - J. Mori AU - H. Asou AU - E. Michael Chan AU - Y. Fujiwara PY - 2015 JO - European Journal of Cancer DO - 10.1016/s0959-8049(16)30179-4 UR - https://doi.org/10.1016/s0959-8049(16)30179-4 ER -
APA
Kondo, S., Yamamoto, N., Tamura, K., Tanabe, Y., Iwasa, S., Shimomura, A., Shibasaki, Y., Ogasawara, K., Turner-Jones, K., Mori, J., Asou, H., Chan, E. M., & Fujiwara, Y. (2015). 314 Phase 1 study of abemaciclib, a CDK 4 and 6 inhibitor, as a single agent for Japanese patients with advanced cancer. European Journal of Cancer. https://doi.org/10.1016/s0959-8049(16)30179-4
Source records
- crossref · retrieved 2026-09-25T15:02:16.068Z